DSIP

Plain-English version: DSIP is a tiny protein fragment (a "peptide") that your own brain produces. Scientists found that when they infused it into animals, it increased the slow, high-amplitude "delta" brain waves that mark the deepest stage of sleep — so they named it the Delta Sleep-Inducing Peptide.

It was discovered in 1977 by Swiss researchers Guido Schoenenberger and Marcel Monnier, who collected blood from the cerebral (brain) veins of rabbits during electrically-induced sleep, isolated the active substance, and identified it as a nine-amino-acid peptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Infused into the brain ventricles of other rabbits, it enhanced delta-EEG (deep-sleep) activity — the founding observation the whole field is built on.^[1]

Here is the twist that matters for a skeptic: despite the name, DSIP is not a simple "sleep switch." Later work described it as a broad neuromodulator with effects reaching well beyond sleep — into the stress response, pain processing, body temperature, and several hormone systems.^[2] And nearly 30 years after its discovery, a careful 2006 review concluded the evidence that DSIP is a genuine, dedicated sleep factor remains weak: no one has ever isolated a DSIP gene, a precursor protein it is cut from, or a specific receptor it binds. The authors literally titled it "a still unresolved riddle."^[8] That does not mean DSIP does nothing — the human sleep studies below are real — but it does mean the mechanism is genuinely unsettled, and anyone selling certainty is overselling.

DSIP is a natural human compound, but there is no approved DSIP medicine anywhere in the world. What you can buy is sold strictly as a "research" chemical. For the full legal picture, see Are Peptides Legal?

Takeaway first: Nobody can point to a single, confirmed molecular target for DSIP in humans — that is the honest headline. What the research does show is a set of consistent effects: it shifts sleep toward deeper delta activity, it dampens the stress-hormone (cortisol) response in animals, and it touches several other hormone and pain systems. Below is what the verified studies actually found, and where the trail goes cold.

1. Sleep architecture — nudging toward deep sleep (the founding effect)

The original finding was electrophysiological: infused into the brain, DSIP increased delta-wave EEG activity, the slow brain rhythm of the deepest non-REM sleep stage that is tied to physical recovery.^[1] Crucially, the human work that followed described DSIP as normalizing disturbed sleep rather than sedating — improving how sleep is structured instead of forcing unconsciousness the way a sedative does.^[3] Evidence level: rabbit EEG for the mechanism, small human studies for the outcome.

2. Stress axis (HPA) modulation — animal evidence

Your stress response runs through the hypothalamic-pituitary-adrenal (HPA) axis, ending in the release of cortisol. In rats, intravenous DSIP at 5–30 micrograms per kilogram significantly reduced the corticosterone (the rat equivalent of cortisol) surge triggered by CRF, the brain signal that starts the stress cascade — suggesting DSIP dampens the stress response at a central/pituitary level.^[5] Evidence level: rats. This is the mechanistic basis for the "stress-buffering" claims — but it has not been reproduced as a controlled human outcome.

3. Hormone (endocrine) modulation — animal evidence

DSIP also touches reproductive hormones. In rats, it stimulated the release of luteinizing hormone (LH) — but not follicle-stimulating hormone (FSH) — apparently by acting at a site in the hypothalamus.^[6] This selective, hypothalamic action is why DSIP is described as an endocrine modulator, not just a sleep peptide. Evidence level: rats; the human relevance is unknown.

4. Neuroprotection — a rare recent animal study

In a 2021 rat model of focal stroke (middle cerebral artery occlusion), intranasal DSIP at 120 micrograms per kilogram — given before the stroke and for seven days after — produced significant recovery of motor function on the rotarod balance test. Notably, the honest detail: the reduction in the size of the brain injury (infarct) itself was not statistically significant.^[7] Evidence level: rats; a functional-recovery signal without a confirmed structural effect.

What we do NOT know

This is the part vendors skip. There is no isolated DSIP gene, no identified precursor protein, and no cloned receptor — so the exact molecular machinery is unknown.^[8] There is no established human pharmacokinetic profile (how it is absorbed, distributed, and cleared in people), and DSIP is broken down quickly in the bloodstream. The effects above are real published findings, but the sleep outcomes rest on small old studies and the hormone/stroke mechanisms are rat data. Mechanism in animals does not guarantee benefit in humans.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. DSIP is unusual among research peptides in that it does have some genuine human sleep data — but it is old (1980s), small (a few dozen people total), and predates modern trial standards. Treat everything here as preliminary and historical, not established.

Sleep quality and delta-wave activity (the best human case)

Claim: may deepen and normalize disturbed sleep. Mechanism: enhanced delta-EEG (slow-wave) activity and restructured sleep rather than sedation. Population: chronic insomniacs in small European double-blind studies. Effect: in one double-blind study of six middle-aged chronic insomniacs, intravenous synthetic DSIP produced longer sleep duration and higher sleep quality with fewer interruptions and — importantly — no daytime side effects.^[4] In a broader series of five double-blind studies using single and repeated IV DSIP, four consecutive injections normalized disturbed sleep, and subjects reported improved daytime alertness and stress tolerance rather than sedation.^[3] Limitation: sample sizes were single digits to low double digits, the route was intravenous (not the subcutaneous injection sold today), and there are no modern replications. This is a promising historical signal, not proof.

Circadian / phase-shift sleep problems

Claim: may help reset a badly-timed sleep schedule. Mechanism: presumed action on sleep-timing regulation. Population: a single patient with delayed sleep-phase insomnia. Effect: intensive DSIP treatment advanced the patient's main sleep phase by roughly five hours and enabled them to withdraw from benzodiazepines.^[9] Limitation: this is a single-patient case report — the lowest tier of clinical evidence. It is hypothesis-generating, nothing more.

Stress and cortisol modulation

Claim: may blunt an over-active stress response. Mechanism: dampening of CRF-driven cortisol release at a central level. Population: rats. Effect: IV DSIP (5–30 mcg/kg) significantly reduced CRF-induced corticosterone release.^[5] Consistent with this, the human sleep studies noted better daytime "stress tolerance."^[3] Limitation: the direct cortisol evidence is entirely rat data; the human stress-tolerance reports are subjective and secondary to the sleep studies.

Hormone (endocrine) effects

Claim: may modulate reproductive and other hormones. Mechanism: hypothalamic action. Population: rats. Effect: DSIP selectively stimulated LH (but not FSH) release via a hypothalamic site.^[6] Early reviews also catalogued effects on cortisol, growth hormone during sleep, and other axes, though many were inconsistent.^[2] Limitation: animal data; the clinical significance in humans is unclear, and these are reasons for caution (see side effects) as much as claimed "benefits."

Pain and neuroprotection

Claim: may raise pain thresholds and support recovery after brain injury. Mechanism: interaction with endogenous opioid systems (pain) and neuroprotection (stroke). Population: animal models and older reviews. Effect: early reviews described analgesic and opioid-modulating effects,^[2] and a 2021 rat stroke study showed significant motor recovery with intranasal DSIP — though the reduction in brain-injury size was not statistically significant.^[7] Limitation: no controlled human pain or stroke trials exist.

The honest bottom line on "benefits"

• The sleep data are real but thin and old. A few dozen insomniacs in 1980s European studies is the entire modern-quality human base — no Phase 2/3 trials have ever been run.^[3]
• The hormone and stroke work is animal-only. Rat findings do not translate automatically to people.
• The core biology is unresolved. With no isolated gene or receptor, even the "how" is uncertain.^[8]
• Anecdotes are not data. Enthusiastic online reports of great sleep cannot substitute for controlled trials.

Read this first: there is no modern trial that establishes an optimal human DSIP dose, and there is no validated subcutaneous dose at all. The published human sleep work used intravenous DSIP, and the rat mechanistic work used specific weight-based IV or intranasal doses. The "100–300 mcg before bed" figures you see on vendor sites are practitioner and community convention — not trial-derived numbers. We describe them for completeness and harm reduction, not as medical guidance.

What the published research actually used

Source	Species	Route	Dose used
Human insomnia studies[3][4]	Humans	Intravenous	Single & repeated IV injections (weight-based, historically cited in the ~25–100 mcg/kg range)
Cortisol / HPA study[5]	Rats	Intravenous	5–30 mcg/kg
Focal-stroke study[7]	Rats	Intranasal	120 mcg/kg

Community / practitioner protocols (convention, NOT trial-derived)

Goal	Commonly cited dose	Frequency	Timing
Sleep	100–250 mcg	Once daily	30–60 minutes before bed
Stress / general	100–300 mcg	Once daily	Evening (or morning)

These are almost always given subcutaneously (a small injection into the fat under the skin), even though the human evidence base is intravenous. That gap — real data on one route, common use on another — is exactly why these numbers should be treated as unvalidated.

Reconstitution math, with a worked example

DSIP ships as a lyophilized (freeze-dried) powder, usually in 2 mg or 5 mg vials, that must be mixed with bacteriostatic water before use. The core formula:

Concentration (mcg/mL) = vial amount (mcg) ÷ water added (mL)

Worked example: take a 5 mg vial (that is 5,000 mcg) and add 2 mL of bacteriostatic water. That gives 5,000 ÷ 2 = 2,500 mcg/mL. To draw a 250 mcg dose: 250 ÷ 2,500 = 0.10 mL, which is 10 units on a standard 100-unit insulin syringe.

Vial	BAC water	Concentration	100 mcg	250 mcg
2 mg	2 mL	1,000 mcg/mL	0.10 mL (10 units)	0.25 mL (25 units)
5 mg	2 mL	2,500 mcg/mL	0.04 mL (4 units)	0.10 mL (10 units)

Preparation steps: wipe the vial stopper with alcohol; draw the water; inject it slowly down the inside wall rather than blasting the powder; swirl gently (do not shake) until dissolved; label the vial with the date and concentration. Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for a full walkthrough.

Cycle length and timing

• Timing: for sleep, the convention is to dose 30–60 minutes before intended sleep time. There is no fasting requirement — food does not appear to affect DSIP's sleep effects.
• Cycle length: community protocols typically run 2–4 weeks, sometimes with intermittent (every-other-day) dosing. These durations are convention, not trial-derived.
• Tolerance: some reports suggest the effect may fade with continuous daily use, which is the usual rationale for cycling or intermittent dosing.
• Storage: keep lyophilized vials cold and dark (freezer for long-term, 2–8 °C for shorter periods); refrigerate reconstituted solution at 2–8 °C and use within about 28 days. See the peptide storage guide.

None of the above is a recommendation to self-administer an unapproved compound — it is a description of how research and community doses are structured.

Straight talk: in the published European studies, DSIP was generally well tolerated at research doses, with no serious adverse events reported and — notably — no daytime sedation.^[4] But those studies were small, old, and intravenous, and modern Phase 3 safety standards have never been applied to DSIP. So this is limited reassurance, not proof of safety. A separate and under-appreciated risk is product quality: unregulated "research" vials vary widely, and contaminants can cause effects that get blamed on the peptide.

Reported and plausible side effects

Effect	Frequency	Notes
Injection-site redness/irritation	Common at site	Transient; typical of any subcutaneous injection
Vivid or unusual dreams	Reported	Consistent with changes in sleep architecture; some find it interesting, some distressing
Mild residual morning drowsiness	Occasional	Milder than benzodiazepines or Z-drugs; often dose- or timing-related
Mild headache	Uncommon	Usually transient, first few doses
Mild mood change (either direction)	Uncommon	Both improvements and mild low mood have been described
Subtle hormone shifts (cortisol, LH, GH)	Documented in animal/early work	Usually modest at research doses; see below

No serious adverse events were reported in the published literature at the doses studied.^[4] That is genuinely encouraging — but remember the total human sample across all these studies is a few dozen people, so rare or long-term risks simply could not have been detected.

Endocrine and hormonal considerations

Because DSIP nudges several hormone systems in animal studies — reducing CRF-driven cortisol,^[5] selectively stimulating LH,^[6] and touching growth hormone during sleep in older reviews^[2] — there is a theoretical reason for caution in people with hormonal conditions. These effects are typically modest and are not commonly reported as problematic, but they justify extra care in anyone with adrenal insufficiency (the cortisol-lowering effect could compound), pituitary or HPA-axis disorders, or those already on hormone therapy (including growth hormone).

Who should avoid DSIP

• Pregnancy and breastfeeding: no controlled data exist — avoid.
• Adrenal insufficiency or known HPA-axis dysfunction: theoretical concern given the cortisol-lowering signal.
• Serious psychiatric conditions (active major depression, bipolar disorder) or severe insomnia: DSIP is not a substitute for evidence-based first-line treatment.
• Severe liver or kidney impairment: not studied.
• Known hypersensitivity to DSIP or formulation excipients.

Drug interactions (mostly theoretical)

• Benzodiazepines, Z-drugs, opioids, alcohol: theoretical additive sedation. DSIP itself is not strongly sedating, but combining CNS depressants is poor practice.
• Blood-pressure medication: minor BP-lowering effects were noted in some early reports — monitor when starting.
• Other peptides or drugs affecting cortisol or growth hormone: theoretical additive endocrine effects.

What to do if you experience side effects

• Morning grogginess: lower the dose or move it earlier in the evening.
• Vivid or distressing dreams: reduce the dose or discontinue if persistent.
• Mood worsening or persistent daytime fatigue: discontinue and look for other causes; consider an HPA-axis evaluation if symptoms persist.
• Any allergic reaction: stop immediately and seek medical evaluation.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: DSIP is an unregulated research compound, so purity and identity vary enormously between suppliers. For an unproven peptide, contamination is arguably a bigger practical risk than the peptide itself. Learning to read a Certificate of Analysis (COA) is the single most useful skill here.

What a credible product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected molecular weight for the nine-amino-acid sequence (~848 Da for the free acid).
• Batch-specific results: the COA should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial — not a pre-mixed "ready to use" liquid.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• Pre-mixed liquid peptide (shorter shelf life, higher contamination risk)
• Prices far below the market
• Explicit human-use or medical claims, which signal a non-compliant, higher-risk vendor

Legal and regulatory status (2026)

DSIP is not FDA-approved for any use, and there is no approved DSIP drug product anywhere. It is sold only for "research" purposes. There is, however, a live 2026 development worth understanding accurately — because there is a lot of hype around it.

Under the name Emideltide, DSIP (both the free base and acetate forms) is on the agenda for the FDA's Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23–24, 2026 (Docket FDA-2025-N-6895), for possible inclusion on the Section 503A list of bulk substances that licensed pharmacies may compound. The indications named for discussion are opioid withdrawal, chronic insomnia, and narcolepsy.^[10]

Two things beginners should not misread: first, a PCAC recommendation is advisory and non-binding — it is not FDA approval, and it is not a finding that DSIP works. Second, even a positive vote would require formal notice-and-comment rulemaking before licensed pharmacies could legally compound it, and that process has historically taken years rather than months. Until that entire process concludes, DSIP remains a research-only compound. For the full legal breakdown, read Are Peptides Legal?

Update — the panel voted against it: on July 24, 2026, the PCAC rejected emideltide (DSIP) for the 503A list by a narrow 6–7–1 vote — the only one of the seven peptides reviewed that the committee declined to recommend. This leaves DSIP's status unchanged, not worsened: it was not banned, and it remains exactly as available as it was before the vote. See our report on the FDA advisory panel's July 2026 vote against adding DSIP to the compounding list for the full two-day record.

Note: an earlier FDA advisory-committee calendar link for this meeting now returns a 404; the citation below points to the official Federal Register notice instead.